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Three novel acetato-bridged dinuclear copper(II) complexes with 5-nitroimidazoles (CuAcNtrim) and the
known copper–acetato–metronidazole have been prepared by an environment-friendly route and spec-
troscopically characterized. The CuAcNtrim compounds of formula [Cu2(l-O2CCH3)4Ntrim2], where
Ntrim = metronidazole (1), secnidazole (2), tinidazole (3) or nimorazole (4), exhibit dimeric copper–
acetato paddle-wheel structures with Ntrim axial ligands coordinated to copper(II) ions through the N3
atoms of the imidazole rings. EPR data indicate antiferromagnetic behavior for this novel series of copper
complexes. The constant coupling has been found to decrease along with the increasing of basicity of the
Ntrim axial ligand. The CuAcNtrim complexes and the correspondent Ntrim parent drugs have shown
radiosensitizer properties for Hep2 (human larynx cancer) cell line in vitro. The best enhancement of radi-
osensitizer activity upon coordination of the Ntrim drug to copper(II) has been found for the nimorazole
compound which has the strongest Cu–Ntrim bond and exhibits the highest lipophilicity within the
series of CuAcNtrim complexes.
 2010 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Many classes of transition metal complexes are able to enhance
cellular radiation damage both in vitro and in vivo. Three principal
mechanisms have been suggested for radiosensitization by metal
complexes: DNA-binding with subsequent consequences to repair
processes, thiol depletion and electron-afﬁnic mechanism imply-
ing reduction of the metal complex and subsequent ﬁxation of
damage on the intracellular target of radiation, the DNA [1]. Cop-
per(II) ion is well known to modify the radiation response in both
mammalian and bacterial cells [2,3]. The radiosensitizing mecha-
nism in mammalian cells may involve reduction of copper(II) to
copper(I) [2]. More recently, it has been found that: radiosensitiza-
tion process may be related to radiation induced DNA damage [4];
biological damage sensitized by copper ions might involve nucleo-
bases [5]; and copper complexes with different structural features
can bind with double-helical DNA and promote double-strand DNA
damage [6]. Steady-state and pulse radiolysis studies with nucleicSilva).
acultad de Ciencias, Univers-
ac, Casilla 31–139, Lima, Perú.
anas, Universidade Federal do
Brazil.
evier OA license.acid bases and polynucleotides showed that copper(II) ion and its
complexes can be effective in sensitizing radiation-induced nucle-
obase damage [7,8].
Metal complexes with imidazoles have been investigated as
radiosensitizers for tumors cells [1,9]. Particularly, nitroimidazole
drugs exhibit radiosensitizer activity that increases hypoxic cells
sensibility to radiation to enhance treatment efﬁciency in cancer
radiotherapy – in addition to a wide variety of other therapeutic
properties [10,11]. Metronidazole [Metrim, 2-(2-methyl-5-nitro-
imidazol-1-yl)ethanol] (Fig. 1) a member of 5-nitroimidazole
(Ntrim) class of drugs, sensitizes efﬁciently hypoxic cells to c-radi-
ation induced damage. However, it shows toxicity in the clinical
doses required for radiation therapy of cancer cells. The complex-
ing ability of Metrim to copper(II) was studied for gamma radioly-
sis and radiosensitization of thymine [12,13], and structural and
magnetic properties of a copper–acetato–Metrim compound have
been reported [14,15]. However, no studies involving hypoxic cells
was found for this compound although the inﬂuence of copper(II)
ion and some synthetic aminocarboxylic derivatives on radiosensi-
tivity of Escherichia coli has been described recently [16].
The present work describes the interaction of copper(II)–aceta-
to (CuAc, [Cu2(l-O2CCH3)4(H2O)2]) with Metrim and three other
5-nitroimidazole drugs shown in Fig. 1: secnidazole [Secnim,
1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol]; tinidazole
[Tinim, 1-(2-ethylsulfonylethyl)-2-methyl-5-nitro-imidazole] and
Fig. 1. General structure of 5-nitroimidazole (Ntrim).
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The novel copper–acetato–Ntrim (CuAcNtrim) complexes have
been prepared, spectroscopically and magnetically characterized
and investigated for radiosensitizer properties.2. Experimental
2.1. Materials
All reagents and solvents were reagent grade and used without
further puriﬁcation: metronidazole (Sigma), secnidazole (Rhodia),
tinidazole (Pﬁzer), nimorazole (Abbot), copper acetato hydrate
(Mallinckrodt) and solvents (Merck).
2.2. Preparation of CuAcNtrim complexes
Complexes 1–4 were prepared by the following general proce-
dure: ethanolic hot solutions of CuAc (30 cm3) and the correspon-
dent Ntrim drug (20 cm3) [CuAc/Ntrimmolar ratios were according
to 1:3.5 for compound 1 (0.40:0.60 g/g) and 1:3 for compounds 2
(0.25:0.35 g/g), 3 (0.25:0.46 g/g) and 4 (0.25:0.42 g/g)] were mixed
and stirred at room temperature for approximately 2 h. The vol-
ume of the solvent was reduced to 10 cm3 by slow evaporation
at room temperature, except for 2 which had the volume reduced
to 5 cm3 by heating the solution at 60 C. The solids were ﬁltered
off, washed with ethanol and dried in vacuum.
2.2.1. [Cu2(Ac)4 (Metrim)2] (1)
Yield 60%. Anal. Calc. for C20H30N6O14Cu2: C, 34.0; H, 4.3; N,
11.9. Found: C, 34.3; H, 4.1; N, 12.0%. Decomposition: T > 150 C.
FTIR, m (cm1): 3432m br, 3153 w, 3150–2800 w, 1623 vs,
1549 m, 1475m, 1432 s, 1369m, 1268m, 1188m, 1144 w, 1084
w, 1043 w, 988 w, 830 w, 745 w, 685m, 627 w.
2.2.2. [Cu2(Ac)4(Secnim)2] (2)
Yield 57%. Anal. Calc. for C22H34N6O14Cu2: C, 36.0; H, 4.7; N,
11.5. Found: C, 36.3; H, 4.4; N, 11.5%. Decomposition: T > 175 C.
FTIR, m (cm1): 3342 m br, 3137 w, 3130–2800 w, 1619 vs 1541
m, 1512 sh, 1492 m, 1474 s, 1425 s, 1372 m, 1300 w, 1269 m,
1193 m, 1148 w, 1133 w, 990 w, 830 w, 739 w, 682 m, 626 w.
2.2.3. [Cu2(Ac)4(Tinim)2] (3)
Yield 70%. Anal. Calc. for C24H38N6S2O16Cu2: C, 33.6; H, 4.5; N,
9.8. Found: C, 33.4; H, 4.0; N, 9.7%. Decomposition: T > 175 C. FTIR,
m (cm1): 3432m br, 3158 w, 3140–2900 w, 1629 vs, 1556 s, 1519
w, 1492 m, 1478 m, 1458 sh, 1427 vs, 1373 m, 1365 m, 1351 m,1310 s, 1267 s, 1209 m, 1173 w, 1134 s, 1062–866 w, 830 mw,
792 mw, 742 mw, 682 m, 627 w.
2.2.4. [Cu2(Ac)4(Nimim)2] (4)
Yield 60%. Anal. Calc. for C26H40N8O14Cu2: C, 38.3; H, 4.9; N,
13.7. Found: C, 38.3; H, 4.6; N, 14.0%. Decomposition: T > 150 C.
FTIR, m (cm1): 3430 w br, 3137 w, 3130–2800 w, 1629 vs, 1537
s, 1521 s, 1472 s, 1434 s, 1370 s, 1300 w, 1263 w, 1236 w, 1201
w, 1170 w, 1141 w, 1125 m, 1112 s, 1016 w, 933 w, 860 w, 828
w, 741 w, 684 m, 648 m, 627 w.
2.3. Physical measurements
Elemental analyses were performed by the Analytical Center of
the Chemistry Institute in São Paulo University using a Perkin–El-
mer 2400 CHN analyzer. Atomic emission analyses for copper were
conducted on Spectroﬂame Co. equipment (k 327.396 nm). FTIR
spectra were recorded on a BOMEM MB-100 (as KBr pellets;
4000–400 cm1) and an ABB BOMEM MB-102 (as Nujol mulls/CsI
windows; 500–190 cm1) spectrophotometers. UV–Vis spectra in
solution were recorded on a Hitachi U-3000 or a Shimadzu UV-
1650PC spectrophotometer and spectra of solids were registered
on a Guided-wave 260 equipped with optical ﬁber or a Shimadzu
UV-2401PC (samples diluted with BaSO4) equipped with an inte-
gration sphere X-band spectrophotometer. EPR spectra were ob-
tained at room temperature on a Bruker EMX instrument using
polyethylene tubes and DPPH (a,a0-diphenyl-b-picrylhydrazyl) as
frequency calibrant (g = 2.0036). Room temperature magnetic sus-
ceptibilities were measured by Faraday technique with a Cahn
electrobalance 7500 in a magnetic ﬁeld of 1T with the calibrant
Hg[Co(SCN)4] (16.44  106 c.g.s. units/Gauss). Variable-tempera-
ture (30–300 K) magnetic susceptibility measurements were car-
ried out on powdered samples with a SQUID magnetometer
under applied magnetic ﬁeld of 500 Oe. The susceptibility data
were corrected for diamagnetic contributions of the constituent
atoms.
2.4. Biological assays
2.4.1. Preparation of CuAc, CuAcNtrim and Ntrim solutions
Compound CuAc and derivatives 1–4 were individually dis-
solved in water to give 3 mmol dm3 concentration stock-solu-
tions. Then, 3.0 cm3 of these stock-solutions were diluted with
2.0 cm3 MEM (Minimum Eagle’s Medium supplemented by 10% fe-
tal calf serum) giving the correspondent 100%-work-solutions.
Sterilization was performed by ﬁltering the 100%-work-solutions
through a 0.22 lm Millipore ﬁlter membrane and ﬁnal concentra-
tions determined by atomic emission were (in mmol dm3): 0.16
(CuAc); 0.95 (1); 1.54 (2); 1.50 (3) and 1.60 (4). Subsequently,
these sterile 100%-work-solutions were serially diluted with
MEM to 50%, 25%, 12.5% and 6.25% giving ﬁnal solutions within a
range from 1600 to 160 lmol dm3 drug concentrations. The
solutions of the Ntrim organic drugs were prepared by similar pro-
cedures giving 100%-work-solution concentrations (mmol dm3)
of 43.7 (Metrim), 40.7 (Secnim), 15.4 (Tinim) and 37.2 (Nimim).
2.4.2. Cytotoxicity assays
Cytotoxicity assays were carried out in vitro by using cell cul-
ture of mouse connective tissue NCTC clone 929 obtained from
American Type Culture Collection (ATCC) by neutral red uptake
methodology according to Ciapetti et al. [17].
The cells were maintained in MEM (Minimum Eagle’s Medium
with 10% fetal calf serum, 0.1 mmol dm3 non-essential amino
acids and 1.0 mmol dm3 sodium piruvate). Cells were detached
with 0.2% trypsin and 0.02% EDTA, and the cellular suspension
was adjusted to 5  103 to 5  104 cells cm3. A 0.2 cm3 volume
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and incubated (INC: incubation under humidiﬁed air atmosphere,
5% CO2, at 37 C) for 24 h. After that, culture medium was replaced
by 0.2 cm3 of each CuNtrim or Ntrim solution, in triplicate. Extract
of PVC used as negative control and 0.02 % phenol solution used as
positive control received the same dilution treatment. Each well of
control-cells received 0.2 cm3 MEM. The microplate was main-
tained in INC for 24 h. After this time, the culture medium and
solutions were replaced by neutral red dye-containing MEM
(50 lg cm3). After incubation (INC) for 3 h, the microplates were
washed twice with phosphate buffer (PBS) and 1% CaCl2 in 0.5%
formaldehyde solutions. Each well received 0.2 cm3 of 1% acetic
acid in 50 % ethanol and the optical densities (OD) were measured
at 540 nm with an ELISA reader spectrophotometer Sunrise from
Tecan. The determination of the cytotoxicity index (IC50), i.e., the
concentration of the solution which injures or kills 50% of cell pop-
ulation in the assay, was based on the graphic of cell viability per-
centages (in relation to cell control 100 % viability) in function of
the concentrations of CuNtrim or Ntrim solutions.
2.4.3. Gamma-radiation lethal dose (c-LD50) assays
Experiments were carried out in vitro under anaerobic condi-
tions for Hep2 cell line (human larynx cancer cell of American Type
Culture Collection (ATCC-CCL23) by adapted neutral red uptake
methodology [17]. The cells were maintained in MEM and were de-
tached with 0.2% trypsin and 0.02 % EDTA. A suspension of about
1.0  105 cells cm3 was seeded in each well of 96 microplate-
wells and incubated in INC for 24 h. After that, culture medium
was changed by fresh MEM and the microplate was introduced
into partially opened plastic boxes and enclosed into plastic bags
under microaerophilic conditions created by using CampyGen sa-
chets (Oxoid). Then, the samples were exposed to c-rays from a
panoramic 60Co source with 0.89 Gy min1 dose rate for periods
of time correspondent to doses of 0; 50 and 100 Gy. Culture med-
ium were changed again and the samples were incubated (INC) for
24 h. The culture medium was replaced by a solution of neutral red
dye-containing MEM (50 lg cm3) and the procedure was fol-
lowed according to that described in Section 2.4.2. The cell viability
was calculated in relation to control cell – non-irradiated micro-
plate (zero Gy = 100%) and the c-radiation lethal dose (c-LD50)
was determined.
2.4.4. Radiosensitizer assays
The experimental procedure was similar to that described for c-
LD50 assays (Section 2.4.3). However, before being submitted to
microaerophilic conditions, the microplate culture medium was
replaced by a 100 lmol dm3 CuAcNtrim or MEM containing
Ntrim. The samples were exposed to 60Co c-rays for periods of time
correspondent to doses of 0; 3; 6 and 10 Gy which were lower than
those used for determination of c-LD50.3. Results and discussion
3.1. Synthesis
The preparation of CuAcMetrim previously reported in the liter-
ature [14,15] was carried out by heating under reﬂux for 6 h an
ethanolic mixture of CuAc and Metrim. In the present work, this
compound has been re-prepared by an alternative environment-
friendly route which was also found to be appropriate to synthe-
size the other three novel copper(II)–acetato–Ntrim complexes.
The products from reactions of CuAc with Ntrim drugs in ethanol,
at room temperature (25 C), are formed by the replacement of
the two axial water molecules in the precursor by two Ntrim drugs
and exhibit general formula [Cu2(l-O2CCH3)4(Ntrim)2].3.2. Electronic and Infrared spectra
The absorption bands observed in the electronic absorption
spectra of the copper(II) complexes 1–4 are listed in Table 1. Meth-
anol solutions of these complexes show an intense UV band at kmax
300 nm (e  30.000–45.000 mol1 dm3 cm1) with shoulder at
235 nm. These bands are located at similar maximum wave-
lengths for the correspondent non-coordinated 5-nitroimidazoles
drugs and might be ascribed to Ntrim intraligand (IL) transitions.
The broad absorption band at Vis–NIR region (Table 1) with kmax
centered around 700 nm (e  140–180 mol1 dm3 cm1) is as-
signed to the characteristic copper(II) d–d transition (band I:
dxy,yz? dx2y2 ) [18–20]. The other two expected bands (band II,
charge transfer, ca. 300 nm, and band III, ca. 256 nm) for copper(II)
complexes are probably overlapped with Ntrim ligand bands. The
UV–Vis–NIR reﬂectance spectra show that the broad band assigned
to copper(II) d–d transition is centered at kmax in the region of 700–
750 nm (Table 1) for the CuAcNtrim compounds in solid state. The
energy of this electronic transition might depend on the nature of
the Ntrim axial ligand according to the order Nmim > Tinim > Sec-
nim Metrim. However, a reliable correlation cannot be made be-
cause of the broadness of these bands (for example, the copper(II)
d–d transition for compound 1 in microcrystalline form has been
previously reported at a lower kmax (710 nm) [14,15]). Additionally,
the spectra of all CuAcNtrim complexes have a shoulder located at
370 nm that might be ascribed to band II and give evidence for a
carboxylato-bridged structure for the dinuclear copper(II) com-
plexes with axial 5-nitroimidazoles [4, 21].
The electronic spectra of the four CuAcNtrim complexes in solu-
tion have been monitored in a time range from 0 h to 27 h. No sig-
niﬁcant absorbance changes have been observed neither for UV
(235 (sh), 300 nm) nor for VIS (700 nm) bands. These results
indicate that the copper complexes exhibit good stability in solu-
tion since dissociation of Ntrim ligands has not been detected to
be appreciable in the range of time investigated here.
Selected absorption bands in FTIR spectra of compounds 1–4 are
shown in Table 1 together with main bands of the non-coordinated
Ntrim drugs for comparison. The ma(OCO) and ms(OCO) stretchings
of acetato ligands in CuAcNtrim spectra appear at wavenumber re-
gions of 1619–1629 cm1 and 1425–1434 cm1, respectively, giv-
ing Dm(COO) values of 190–200 cm1 in good agreement with
symmetrical bridging coordination mode of the acetato ligands
[22]. The d(OCO) and q(OCO) angular deformations are located
around 685 and 627 cm1 respectively. The main Ntrim bands
are tentatively ascribed here by comparison with the IR spectra
of some other imidazoles and their metal complexes [15,22–24].
The major changes in CuAcNtrim spectra in relation to the corre-
spondent Ntrim ligand spectra occur in the region of the imidazole
ring vibrations. The typical m(C@N) imidazole ring stretching bands
in CuAcNtrim spectra are shifted to higher wavenumbers
(1537–1556 cm1) in relation to those of the correspondent non-
coordinated Ntrim drugs (1525–1536 cm1) and indicate that the
coordination of Ntrim to copper(II) is through the N3 atom of the
imidazole ring. The comparison of wavenumbers for the CuAcN-
trim series shows a slight increasing of the m(C@N) vibrational fre-
quency along with the following order for Ntrim axial ligands:
Nimim < Secnim < Metrim < Tinim. This order is in good agreement
with the basicity [25] of the Ntrim drug axial ligand – the most ba-
sic drug Nimim coordinates to Cu(II) more tightly and hence the
CuAcNimim exhibits the weakest C@N3 ring bond. On the other
hand, the ma(NO2) (1475 cm1) and ms(NO2) (1370 cm1)
stretching vibrations remain in approximately the same position
as observed for the non-coordinated Ntrim drugs. The splitting of
these two bands, Dm(NO2) 105 cm1, is similar for all CuAcNtrim
complexes and suggests that the –NO2 group is not involved in the
coordination of Ntrim drugs to the copper(II) [15]. The frequency of
Table 1
Selected UV–Vis–NIR and FTIR** spectral data for compounds 1–4.
Compounds 1–4 (Ntrim drug)
1 (Metrim) 2 (Secnim) 3 (Tinim) 4 (Nimim)
kmax (nm);
[e  103, mol1 dm3 cm1]
(methanol solutions)
235 sh
309 [38]
702 [0.14]
235 sh
309 [45]
700 [0.18]
236 sh
310 [36]
700 [0.18]
230 sh
296 [34]
700 [0.18]
kmax (nm);
(solid state – diffuse reﬂectance)
307
370 sh
750 br
310
370 sh
750 br
315
370 sh
720 br
302
374 sh
700 br
Selected FTIR bands
ma (OCO) 1623 vs 1619 vs 1629 vs 1629 vs
ms (OCO) 1432 s 1425 s 1427 vs 1434 s
m (C@N) 1549 m (1536 s) 1541 m (1528 s) 1556 s (1523 s) 1537 s (1525 s)
ma (NO2) 1475 m (1476 s) 1474 s (1489 s) 1478 m (1478 s) 1478 s (1471 s)
ms (NO2) 1369 m (1370 s) 1372 m (1379 s) 1373 m (1375 s) 1372 s (1370 s)
m (NCNO2) 830 w (826 m) 830 w (825 m) 830 mw (829 m) 828 w (824 m)
ma (SO) – – 1310 s (1302 vs) –
ms (SO) – – 1134 s
(1123 vs)
–
m (COC) – – 1112 s (1112 s)
d (OCO) 685 m 682 m 682 m 684 m
q (OCO) 627 w 626 w 627 w 627 w
m (Cu–O)
m (Cu–N)
352 w
265 w
350 w
260 w
354 w
265 w
360 w
278 w
** Wavenumbers in cm1: br = broad; vs = very strong; s = strong; m = medium; mw = medium-weak; w = weak; sh = shoulder.
Table 2
Magnetic moments (leff) per copper(II) atom, EPR parameters and magnetic
parameters for compounds 1–4.
1 2 3 4
leff (BM) 1.53
1.55 [15]
1.55 1.48 1.40
g\ 2.03 2.01 2.05 2.04
g// 2.16 2.16 2.18 2.19
giso
* 2.07 2.07 2.09 2.09
Dtotal (cm1) 0.27 0.29 0.30 0.30
2J/k (cm1) 390 374 423 319
p 0.012 0.01 0.06 0.01
Na 630  106 340  106 40  106
* giso = 1/3 (g// + 2 g\).
Fig. 2. EPR spectra of compounds 1–4.
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cantly changed upon their coordination to the metal ions. Typical
bands of the substituent groups: ma(SO) of Tinim and m(COC) of Ni-
mim, appear for the correspondent CuAcNtrim complexes at
approximately the same wavenumbers that those observed for
non-coordinated Ntrim drugs. The ms(SO) of Tinim however is
slightly shifted to higher wavenumber for the complex indicating
that this group might be involved in intermolecular interactions.
The involvement of the –SO2 group in other interactions might
be the reason for the highest shifting observed for m(C@N) upon
coordination of Tinim to copper(II) ions. The unique band found
for CuAcNtrim complexes at 350 cm1 might be assigned to cop-
per-(O-acetato) stretching. The new bands at 260–280 cm1
which are not present for CuAc or Ntrim might be due to copper-
(N3) stretchings [26,27]. The highest value for m(Cu–N) is found
for complex CuAcNimim (278 cm1) giving additional evidence
that Cu–Nimin bond is stronger than the Cu–Ntrim bonds of its
analogs.
3.2.1. EPR spectra and magnetic susceptibility behavior
Effective magnetic moments, EPR and magnetic parameters
for compounds 1–4 are shown in Table 2. The effective magnetic
moments (leff) per copper(II) atom at room temperature are in
the range of 1.40–1.50 BM. This range includes the value of CuAc
(leff = 1.45 BM) and other dinuclear copper(II) compounds
[15,28] and suggests the existence of dimeric structures with
interaction between the two copper atoms for CuAcNtrim
complexes.
The EPR spectra at X-band frequency for powdered compounds
1–4 show three signals located at 150–1500, 4540–4640 and
5930–6040 G (Fig. 2) which are respectively assigned to Hz1, H\
and Hz2 [29]. Small resonance signals at 3000–4000 G might be
ascribed to the presence of monomer impurities which are often
observed for carboxylato-bridged copper(II) compounds. The EPR
spectra of the dinuclear copper(II) compounds arise from the com-
bined effects of the anisotropic and antisymmetric exchange and
from the classical dipole–dipole interaction. It can be ﬁtted satis-
factorily using the following spin Hamiltonian (Eq. (1)) for isolated
copper(II) dimers (S = 1) [29,30]:
H ¼ DS2z þ EðS2x  S2yÞ þ bðgzHzSz þ gxHxSx þ gyHySyÞ ð1Þwhere D and E are the zero-ﬁeld splitting parameters, b is the
Bohr magneton, and x, y and z are the principal axes of a coordi-
nating system that is ﬁxed with respect to the Cu–Cu bond. EPR
spectroscopic parameters from room temperature measurements
are shown in Table 2. The spectral features together with the g
Fig. 4. Plot of the constant couplings for CuAcNtrim as a function of pKa values [25]
of the Ntrim ligands (the value of pKa for Secnim has been considered as similar to
that found for the closest analog C7H13N3O4 (or DA 3838).
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number of reported dimeric copper(II)–carboxylato complexes
with axial symmetry [31–34]. The EPR data are characteristic of
tetragonal structures (g// > g\) where the unpaired electron is in
a dx2y2 orbital [35].
The magnetic susceptibility values were plotted as a function
of the temperature and the representative plot for compound 2
is shown in Fig. 3. A broad maximum at the temperature of
approximately 230 K and a clear trend of decreasing values at
lower temperatures are typical of discrete antiferromagnetically
ordered systems [30]. The susceptibility value increases below
20 K, probably due to the presence of small paramagnetic
impurity.
The observed magnetic behavior can be described by the Blea-
ney–Bowers equation combined with an additional term which ac-
counts for the paramagnetic contribution [36] (Eq. (2)):
v ¼ 2Nb2g2=kT½3þ expð2J=kTÞ1ð1 qÞ þ ½Nb2g2=2kTp
þ Na; ð2Þ
where all the terms have their usual deﬁnitions and q is the
percentage of paramagnetic impurity. The spectroscopic splitting
factor giso (obtained from the EPR spectrum) was used as a con-
stant in the ﬁtting processes. This approach was used successfully
for compounds 1–4 and the best ﬁt parameters are shown in
Table 2.
The value of |2J/k| increases along with the following order
based on the Ntrim axial ligand of the dimeric CuAcNtrim carbo-
xylatos: Nimim < Secnim < Metrim < Tinim. Therefore, in this ser-
ies of compounds there is a general trend for coupling constant
to decrease as the Ntrim axial ligand becomes better electron-
donor. The strength of the antiferromagnetic coupling decreases
along with the increasing of the basicity of the axial Ntrim drug-
ligand. A plot of the |2J/k| values for the CuAcNtrim complexes as
a function of the pKa of the Ntrim drugs (pKa values used here
were taken from the literature [25]) shows a |2J/k| vs. pKa corre-
lation that is approximately linear (Fig. 4). The inﬂuence of sev-
eral factors on the constant couplings for carboxylato-bridged
dinuclear copper(II) compounds has been examined by computa-
tional models and shows that the replacement of axial H2O
molecules by NH3 molecules in [Cu2(l-O2CCH3)4(H2O)2], for
example, reduces the strength of constant coupling by 5% [37].
The present work shows that the replacement of the less basic
Tinim by the most basic Nimim reduces the strength of the anti-
ferromagnetic coupling by 25%. Therefore, by changing the Ntrim
ligand according to the basicity it is possible to modulate the
constant coupling for this series of CuAcNtrim compounds for
which structures are shown in Fig. 5.Fig. 3. Temperature dependence of the magnetic susceptibility, vM, for dimeric
compound 2.3.3. Biological assays
The results obtained from the in vitro biological assays are sum-
marized in Table 3.3.3.1. Cytotoxicity assays
The IC50 values determined from cytotoxicity assays (NCTC
clone 929 cell line) indicate that CuAcNtrim compounds are more
cytotoxic to cells than the correspondent non-coordinated Ntrim
drugs (>10 mmol dm3). CuAcMetrim (1) is approximately twice
less cytotoxic than the other three analogs (2, 3 and 4) which show
similar behavior. The IC50 data were used further to establish the
non-toxic levels (100 lmol dm3) for the radiosensitizer assays of
the CuAcNtrim complexes.3.3.2. Gamma-radiation lethal dose assays
The radiation lethal dose, i.e., the radiation dose that kills 50%
cellular population, was determined based on plots (not shown)
of cell viability logarithms as function of radiation doses (0; 50
and 100 Gy). The value of c-LD50 found for Hep 2 cells (34.1 Gy)
provided the radiation dose level to be used for radiosensitizer
assays.3.3.3. Radiosensitizer assays
The cell suspensions were exposed to CuAcNtrim compounds at
concentrations (0.100 mmol dm3) which were below their toxic
levels (IC50). Radiosensitizer properties of CuAcNtrim complexes
and Ntrim drugs were evaluated based on experimental data for
radiation doses of 0, 3, 6 and 10 Gy. Plots of survival fraction (S)
logarithms as function of radiation doses (Fig. 6) were adjusted
to a quadratic linear model (a,b-model) [38]:
ln S ¼ aD bD2 ð3Þ
where S is the survival fraction, i.e., the ratio between the number of
survival cells for a determined radiation dose and the number of
survival cells for a non-irradiated sample; D is the radiation dose;
a and b are constants that correspond, respectively, to one event
and two independent events produced by radiation.
Survival curves on Fig. 6 show that the value of ln S decreases
along with the increasing of radiation doses for all CuAcNtrim com-
pounds. Values of Ds, i.e., the radiation dose required for survival
fraction S, correspondent to S = 0.5 (50% cell survival) and S = 0.8
(80% cell survival) are summarized in Table 3.
Fig. 5. Molecular structures of compounds 1–4.
Table 3
Results obtained from in vitro biological assays.
Data from biological assays Compounds 1–4 (non-coordinated drug)
1 (Metrim) 2 (Secnim) 3 (Tinim) 4 (Nimim)
IC50 (mmol dm3) 0.270 ± 0.001 0.150 ± 0.005 0.140 ± 0.019 0.150 ± 0.009
D0.5 (Gy) 7.1 [8.2] 6.8 [4.0] 6.7 [5.3] 6.3 [8.6]
ER0.5⁄ 1.2 [1.0] 1.3 [2.1] 1.3 [1.6] 1.4 [1.00]
D0.8 (Gy) 2.8 [3.0] 2.4 [1.4] 2.3 [1.8] 3.1 [4.0]
ER0.8⁄ 2.2 [2.0] 2.6 [4.4] 2.7 [3.4] 2.0 [1.5]
a (103 Gy1) 64.7 [65.7] 86.8 [154.3] 76.5 [122.2] 35.8 [32.6]
b1/2 (103 Gy1) 67.1 [48.0] 50.0 [60.8] 64.8 [43.6] 108.6 [74.2]
⁄ER = DoS=DS; D
o
S = radiation dose without radiosensitizer (8.6 Gy for S = 0.5; 6.2 Gy for S = 0.8); DS = radiation dose in the presence of radiosensitizer.
Fig. 6. Survival curves for Hep2 cells irradiated in hypoxic ambient in the presence
of compounds 1–4 (100 lmol dm3) obtained by polynomial adjust to Eq. (4)
(D = radiation at 0.89 Gy min1 dose rate).
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Hep2 cells in hypoxic condition in the presence of the radiosensi-
tizers are in the range from 6.0 to 7.1 Gy. These values are approx-
imately 5-fold lower than the c-LD50 (34.1 Gy). Therefore, all
CuAcNtrim complexes and Ntrim drugs show radiosensitizer activ-
ity and have the ability to enhance the gamma-irradiation effect
for the same cell culture mortality. The D0.5 values show a slightdecreasing from compound 1 (7.1 Gy) to 4 (6.3 Gy). ER0.5 values
higher than 1.0 give evidence for radiosensitizer activity. The
ER0.5 enhancement ratios are approximately similar for all the
CuAcNtrim complexes. However, these values indicate that com-
pounds 1 and 4 show enhancement (20% and 40%, respectively)
of radiosensitizer activity in relation to their Ntrim parent drugs.
The best enhancement of radiosensitizer property upon coordina-
tion of Ntrim drugs is found for CuAcNimim (4). Values of D0.8
(80% cell survival) are also shown in Table 3. These are approxi-
mately 17-fold lower than the c-LD50 (34.1 Gy) and show a trend
that is similar to that observed for D0.5 within the series of CuAcN-
trim and Ntrim drugs. However, ER0.8 values are higher than ER0.5
ratios and show larger differences among the CuAcNtrim com-
plexes with the lowest value found for compound 4. On the other
hand, again compounds 1 and 4 exhibit enhancement (10 % and 25
%, respectively) of radiosensitizer activity in relation to their Ntrim
parent drugs and the best enhancement of radiosensitization upon
coordination of Ntrim is found for CuAcNimim (4).
The curve for the non-drug acetato-bridged copper(II) could not
be adjusted to linear quadratic model and the values of D could not
be calculated for this compound. However, the results (not shown)
obtained for the non-drug indicate that the radiosensitizer effect of
the CuAcNtrim complexes is not dependent only on the Ntrim drug
ligands. Although the CuAcNtrim complexes have been found to be
stable in solution up to 27 h, it is not possible to afﬁrm that the
molecular structure of CuAcNtrim is preserved in the biological
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each molecule of CuAcNtrim carries two molecules of Ntrim
drug (i.e., 100 lmol dm3 of copper complex corresponds to
200 lmol dm3 of Ntrim), the parameters for radiosensitizer activ-
ity of CuAcNtrim complexes would be expected to be about 2-fold
higher than those of the correspondent non-coordinated Ntrim
drugs if the effect was attributed only to released axial Ntrim
drugs. Therefore, a synergistic effect due to the presence of the me-
tal and the Ntrim drug ligands might play important role on the
radiosensitizer activity of the CuAcNtrim complexes.
The ER values (Table 3) of the non-coordinated Ntrim drugs
show that the order (Secnim > Tinim > MetrimP Nimim) of the
Ntrim drug sensitization is not directly correlated to the order of
the reduction potentials of the nitro group [39] which is:
Nimim > Secnim > Tinim > Metrim. Moreover, the most lipophilic
Nimin is also not the best Ntrim radiosensitizer drug in this
in vitro experimental condition for human larynx cancer cell. It
has been suggested in the literature that the biological activity of
nitroimidazoles is dependent on the nitro group in the 5-position
of the imidazole ring and also that the steric protection of the –
NO2 group by substituents in N1 and C2 is necessary. Apart from
the essential nitro group that gives the molecules a high (less neg-
ative) 1-electron reduction potential, it has been proposed, for
example, that the degree of antimicrobial activity depend on the
substituents in C2 and N1, i.e., it either enhances or ablates the res-
onance conjugation of the molecule by its special arrangement in
the molecule as well as the hydrophilic/lipophilic properties of
the molecule. Different substitutions at N1 and C2 also modify
kinetics of these drugs. In addition, nitroimidazoles are able to bind
plasma proteins [11]. Mechanism of action of nitroimidazole drugs
to kill anaerobic protozoa involves several steps that include the
reduction of the nitro group and binding of the reduced drug to
DNA resulting in DNA damage (loss of helical structure, strand
breakage, impaired template function) [11]. Therefore, the under-
standing of the behavior of the radiosensitizer property of drugs
depends on several factors.
In the present work, since the a,b-mathematical model [38] was
used to describe the survival curves of the CuNtrim compounds, an
attempt has been made to compare the values of a and b1/2 param-
eters in order to ﬁnd if there was a relation between these values
and the behavior of the drugs investigated here. It is important
to mention that the a,b-model is not being suggested to explain
the radiosensitizer property of the drugs. It has been used to com-
pare the different results obtained for the enhancement of the radi-
osensitizer activity of CuAcNtrim complexes in relation to their
Ntrim parent drugs. The model is based on the assumption that
the cellular death is caused by the DNA damage and allows to esti-
mate the type of events involved in the radiosensitizer process. A
single event (a > b1/2) indicates that DNA double-strand breaks in
one step while a double event (a < b1/2) shows that double-strand
breaks in two independent steps [40]. Based on this model, we
found that the radiosensitizer process involves a single event
(a > b1/2) for Metrim, Secnim, Tinim, CuAcSecnim (2) and CuAcTin-
im (3). In contrast, a double (two independent) event (a < b1/2) is
involved in the radiosensitizer process for Nimim, CuAcMetrim
(1) and CuAcNimim (4). Therefore, it is possible to suggest that
the Nimim non-coordinated drug and the correspondent CuAcNi-
min complex exhibit unique behavior in comparison with the other
analogs with respect to the radiosensitizer process involving dam-
age to DNA. The existence of double event might account for the
enhancement of radiosensitizer property upon coordination of Ni-
mim drug to copper(II) ions in CuAcNimim (4). Moreover, the slight
enhancement of radiosensitization upon coordination of Metrim to
copper(II) in CuAcMetrim (1) might be explained in a similar way
since in this case a change from single event for the organic drug todouble event for the metal complex appears to occur, although the
value of a very close to that of b1/2 for compound 1.
Additionally, it should be mentioned that along the series of
CuAcNtrim dimeric complexes, the CuAcNimim (4) is the deriva-
tive which carries the most lipophilic Ntrim drug. In contrast to
the free Nimim pro-ligand drug, N3 is coordinated to copper(II)
in the complex. Consequently, the factor lipophilicity of the
CuAcNimim complex may favor its incorporation into cells that
might contribute in signiﬁcant way for its radiosensitizer activity.
A recent report has shown that the structure of metal complexes
and the presence of electron afﬁnic site(s) play important role in
the cellular incorporation and accounts for the activity as radiosen-
sitizer. Copper(II) ion and a copper(II)–NTA (nitrilo triacetic acid)
complex, which are signiﬁcantly uptaken, were found to radiosen-
sitize E. coli cells, in contrast to complexes of ethylene diamine tet-
raacetic acid (EDTA) and imino diacetic acid (IDA) which were not
incorporated into the cells [16].
4. Concluding remarks
In this work we have reported that 5-nitroimidazole drugs axi-
ally coordinate acetato-bridged copper(II) dimer through the N3
atom of the imidazole ring by reacting CuAc with the correspon-
dent Ntrim drugs at room temperature. The dimeric compounds
show antiferromagnetic behavior and the constant coupling de-
creases along with the increasing of the basicity of the Ntrim axial
drug ligand. All CuAcNtrim complexes and their correspondent
Ntrim parent drugs show radiosensitizer activity for Hep2 cell line.
The best enhancement of radiosensitizer activity upon coordina-
tion of Ntrim drug is found for CuAcNimim. It is an interesting re-
sult since this compound has the strongest Cu-Ntrim axial bond
and exhibits the highest lipophilicity within the series of CuAcN-
trim complexes investigated here. Consequently, for this series of
metal compounds, the radiosensitizer property might depend on
the molecular structure of the copper(II)–acetato–Ntrim complex.
Furthermore, the enhancement of radiosensitizer activity upon ax-
ial coordination of Ntrim drug to acetato-bridged copper(II) moiety
might be related to the type of the event in the radiosensitizer pro-
cess involving DNA damage. Finally, the CuAcNimin is a novel
metallodrug that deserves future detailed studies in respect to
radiosensitizer activity.
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